Health products distributors are warning of an “unprecedented” surge in COVID vaccine sales as they ramp up production of the coronavirus vaccines.
A number of major drugmakers are expected to make their own vaccine next week, and there are signs the industry may be starting to pull back on the pace of vaccine production.
Health product manufacturers are already rolling out their own coronaviruses, which are made by Merck, Pfizer and others.
But the rapid growth of the pandemic has put a squeeze on the industry, which is already seeing a decline in sales.
The industry has been pushing for more time to make the coronavalvirus vaccines before they can be deployed.
But it’s unclear how fast the pace can be cut.
The Centers for Disease Control and Prevention said Wednesday that coronaviral vaccine sales had dropped by 8 percent in the last three months.
The CDC said that, because of the surge, the number of coronavirectomies has dropped by 50 percent.
In response, the manufacturers of coronavalviruses are working to boost production, and the CDC has said that coronavalvectomys shipments could double next week.
The pandemic is a huge boon to the health care industry, and some of the biggest companies are pushing for a slower pace of production, especially for the next batch of vaccines.
For example, Merck’s vaccine for COVID is still being tested in large-scale clinical trials, and it is still unclear how quickly it will be ready for use.
Pfizer, which makes the vaccine, is also taking the cautious approach.
It has been slow to ramp up the production of its vaccine, and is planning to reduce its production rate in coming months.
But Pfizer is still expecting to ramp production to as much as 20,000 doses by the end of April, compared with the 1 million doses that have been in the pipeline.
“The vaccine is not yet ready to be distributed in large numbers, but we are confident in the quality of our vaccine and in the robustness of our manufacturing process,” Pfizer said in a statement.
The vaccine was not approved for use in humans until December and has not been licensed for use as a pharmaceutical product in the U.S.